Sclerosing Peritonitis in Patient on Timolol

Baxter-Smith, D. C.

doi:10.1016/s0140-6736(78)91528-3

Cited by 21 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since then, case reports involving other beta blockers have been published including timolol, metoprolol, atenolol, oxprenolol, sotalol and propranolol. 22,23,[29][30][31] Two such case reports describing the association of propranolol and sclerosing peritonitis are summarized in Table 1. 22,31 Each of these cases involved men taking propranolol for 3 months to 2 years for treatment of chronic angina.…”

Section: Discussionmentioning

confidence: 99%

“…These adverse reactions led to practolol being withdrawn from the market in 1975. Since then, case reports involving other beta blockers have been published including timolol, metoprolol, atenolol, oxprenolol, sotalol and propranolol 22,23,29–31 . Two such case reports describing the association of propranolol and sclerosing peritonitis are summarized in Table 1 22,31 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Kalra¹,

Atia²,

McKinney³

et al. 2009

J of Digest Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Kalra¹,

Atia²,

McKinney³

et al. 2009

J of Digest Diseases

View full text Add to dashboard Cite

“…In 1974 Brown et al (167) observed a link between SP and the ␤-blocker practolol; the drug was subsequently found (168)(169)(170)(171)(172)(173)(174)(175)(176)(177)(178)(179)(180)(181)(182)(183)(184)(185) to have been associated with hundreds of cases. Other ␤-blockers implicated include atenolol, metoprolol, propranolol, oxprenolol, and timolol.…”

Section: Sclerosing Peritonitismentioning

confidence: 99%

Peritoneal Sclerosis: One or Two Nosological Entities?

Garosi

Paolo

2000

Seminars in Dialysis

View full text Add to dashboard Cite

The frequency, pathology, animal models, pathogenesis, clinical manifestations, diagnostic criteria, therapy and prevention of peritoneal sclerosis are reviewed. Many of these aspects have a bimodal configuration which suggests that peritoneal sclerosis, usually considered a single pathology in peritoneal dialysis, is actually two distinct nosological entities: simple sclerosis and sclerosing peritonitis. The former is very frequent, with minor anatomical alterations and low clinical impact; it is reproducible in animals by means of peritoneal dialysis, and is clearly due to the poor biocompatibility of peritoneal dialysis solutions. The latter is rare, with radical anatomical alterations and high mortality requiring valid methods of diagnosis, therapy and prevention; it can only be reproduced in animal models by means other than peritoneal dialysis and seems to be due to factors both related and unrelated to peritoneal dialysis.

show abstract

“…Long-term peritoneal stimulation, which can occur with CAPD, is thought to be a primary cause for secondary SEP 45. Other reported associations include abdominal tuberculosis,7 long-term use of β-adrenergic blockers,68910111213 ventriculoperitoneal or peritoneovenous shunts in patients with LC,14 orthotropic liver transplantation,15 and sarcoidosis 16…”

Section: Discussionmentioning

confidence: 99%

“…Other β-adrenergic blockers associated with SEP include timolol,9 metoprolol,12 and atenolol 13. There have been two reports on SEP associated with propranolol administered for the treatment of chronic angina pectoris,1011 and one on SEP in a patient with LC who was taking a propranolol for over 4 years 6.…”

Section: Discussionmentioning

confidence: 99%

Sclerosing encapsulating peritonitis in a long-term propranolol user

Noh

et al. 2016

Intest Res

View full text Add to dashboard Cite

Sclerosing encapsulating peritonitis (SEP) is a rare cause of bowel obstruction that is characterized by the encasement of the small bowel by a thick, whitish, and fibrous membrane. The pathophysiology of SEP is poorly understood and preoperative diagnosis is difficult. Previous reports suggest that SEP may be linked to the chronic use of β-adrenergic blockers. A 46-year-old man with liver cirrhosis and end-stage renal disease on hemodialysis presented with recurrent abdominal pain and borborygmi. He had been taking propranolol to prevent bleeding from gastroesophageal varices for the past 15 years. Abdominal computed tomography showed ileal loops encapsulated by soft tissue with dilatation of the proximal small bowel on the right side of the abdomen. Barium follow-through showed conglomerated distal ileal loops with a cauliflower-like appearance. Explorative laparotomy revealed a thick, fibrous, whitish capsule encapsulating the ileal loops. The covering membrane was dissected and excised, resulting in an improvement in symptoms after surgery. Accordingly, a final diagnosis of SEP was made. Due to the lack of other apparent causes for SEP, we conclude that in this case, the long-term use of propranolol may be associated with the development of SEP.

show abstract

Sclerosing Peritonitis in Patient on Timolol

Cited by 21 publications

References 0 publications

Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Sclerosing encapsulating peritonitis associated with propranolol usage: A case report and review of the literature

Peritoneal Sclerosis: One or Two Nosological Entities?

Sclerosing encapsulating peritonitis in a long-term propranolol user

Contact Info

Product

Resources

About